Phase 3 trial in 133 Chinese patients with moderate to severe plaque psoriasis: bimekizumab versus placebo gave higher week-16 PASI 90 (94.0% vs 3.0%) and IGA 0/1 (92.0% vs 3.0%; p<0.001); common adverse events included respiratory infection and abnormal liver function.
RCTn = 133 patients
Cai et al. Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study